

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF FLORIDA

IN RE: ZANTAC (RANITIDINE)
PRODUCTS LIABILITY
LITIGATION

MDL NO. 2924
20-MD-2924

JUDGE ROBIN L. ROSENBERG
MAGISTRATE JUDGE BRUCE E. REINHART

_____ /

THIS DOCUMENT RELATES TO: ALL CASES

PRETRIAL ORDER # 72

Order Requiring Finalization of Registry Information and Certain Short-Form Complaints

Near the inception of this MDL, on April 20, 2020, the Court entered Pretrial Order # 15. At that time, the parties were exploring the possibility that potential plaintiffs (“Claimants”) could preserve their claims without necessarily filing a case in court. DE 547. Each side stood to benefit from such an arrangement. For the Claimants, such an arrangement meant that they need not immediately pay a filing fee and prosecute their case—they could wait to do so until a later stage of the litigation. *See id.* This benefited the Defendants insofar as the Defendants had fewer filed cases to defend against and, relatedly, fewer jurisdictions in which to do so. *See id.* And one important benefit for all parties—Plaintiffs, Claimants, and Defendants—was that the consolidation and preservation of the Claimants’ claims in a central registry would allow for data to be accumulated about the Plaintiffs and the Claimants: the nature of their alleged injuries and a summary of the individual characteristics of the various Plaintiffs and Claimants such as age, location, duration of product use, etc. *See id.* This data was thought to be useful by all parties for the purposes of bellwether trial selection and potential future settlement discussions, and the Court therefore concluded that a registry would “assist in overall effective case management and the orderly and efficient progression of this proceeding.” *Id.* at 1.

Now, almost two years after the inception of this MDL, the time has come for the data in the Registry to be finalized; the pleadings have closed, the Plaintiffs' Leadership has designated the specific cancers it will pursue, the parties have begun the process of preparing *Daubert* challenges on the issue of general causation, and the bellwether trial selection process has begun. For this MDL to proceed in an orderly fashion, both the parties and the Court need to know with some degree of certainty who the Claimants are, what claims they intend to file, and where the Claimants will file their claims. The Court intends to obtain this certainty by setting a date whereupon the information in the Registry, as inputted by Claimants, will become final.¹ The Court has the power to require this finality because each Claimant agreed to be bound to the terms of this Court's Pretrial Orders and further agreed and consented to the authority of this Court to issue additional Pretrial Orders that govern them as Claimants. DE 1408 at 32. Consistent with that grant of authority, the Court hereby **ORDERS** as follows:

Finalization of the Claimants' Intended Forum

1. All Brand Defendants shall provide to Litigation Management, Inc. ("LMI") and Plaintiffs' Co-Lead Counsel all applicable state(s) of citizenship for purposes of diversity analysis within ten (10) days of the entry of this Order. Brand Defendants shall also provide the following information: all specific finished dose formulations of Brand name Zantac manufactured, packaged, or sold, and dates of manufacture, package, or sale of each finished dose Zantac formulation. This shall be provided in a form directed by the Special Master in consultation with LMI, with copies to Adam Pulaski and Tracy Finken, no later than thirty (30) days from the entry of this Order.

¹ Pretrial Order # 15 is not modified or amended with the exception of the provisions set forth therein at page 15, paragraph 5 [DE 547]. This Order supersedes paragraph 5 on page 15 of Pretrial Order # 15.

2. Within two (2) days of the entry of this Order, LMI will provide to each Generic Defendant the information in the current Census Registry database being used for defense mapping that was provided pursuant to Pretrial Order # 50 and citizenship information that has been provided to LMI. Any Generic Defendant that consents to provide any necessary update or correction to such information within thirty (30) days will have no further obligations to provide any information to LMI.

3. LMI shall add a certification box to the Registry interface as soon as reasonably possible and as directed by the Special Master. The purpose of the checkbox is for a Claimant who has registered or a Plaintiff who has filed in this MDL (collectively, the “Registry Participants”) to certify his or her forum of choice. If a Registry Participant does not intend to file his or her claim in federal court, the Registry Participant shall not check the box. If the Registry Participant commits to file his or her claim in federal court (although no Registry Participant is ever required to file suit) then the Registry Participant shall check the box and publish said response to Defendants by no later than June 30, 2022.² In checking the certification box, a Registry Participant also certifies that federal court jurisdiction exists over his or her claims. As a result of the Registry Participant’s certification that federal jurisdiction exists over the Registry Participant’s claims, the Registry Participant must not name a defendant with the same state of citizenship as the Registry Participant as discussed more fully below in paragraph 5.³ The Registry Participants who certify that they will file their lawsuits in federal court will be deemed “Certified Federal Participants.” Within a reasonable time after June 30, 2022, LMI shall provide a report to the Court, Special Master, and all Co-Lead Counsel indicating the total number of Registry

² The Court recognizes that the phrase “Registry Participants” includes Plaintiffs who already have filed cases in this MDL and therefore already have committed to file a claim in federal court. Nevertheless, such Plaintiffs shall check the certification box.

³ Unless the Certified Federal Participant has a basis for federal jurisdiction other than diversity jurisdiction.

Participants, the total number of Registry Participants who allege a Designated Cancer (as defined below), and the number of Certified Federal Participants.

4. This Order is not intended to alter any negotiations that the parties have reached regarding tolling or the right of any Defendant to terminate tolling pursuant to Pretrial Order # 15. Such negotiations, and any agreements reached, regarding tolling are between the parties and are not the subject of this Order. Such negotiation and agreements are not subject to enforcement by the Court unless (i) the parties to the agreement consent to the Court's enforcement of the agreement, and (ii) the Court approves of the parties' consent.

Finalization of the Claimants' and Plaintiffs' Claims in the Registry

5. Every Registry Participant with a Designated Cancer and every Certified Federal Participant with a Non-Designated Cancer must update answers to question 13 of his or her Census Plus Form that he or she previously submitted pursuant to Pretrial Order # 15 ("CPF"), which shall reflect any and all Brand Defendants,⁴ Generic Defendants, Retailer Defendants or others against whom the Certified Federal Participant anticipates filing or intends to file a lawsuit regarding Zantac or any generic equivalent ranitidine product (if any lawsuit is ever filed) ("Anticipated Defendant"). Because each Certified Federal Participant has certified that he or she intends to file in federal court (if he or she elects to file a lawsuit), none of the Anticipated Defendants may have the same citizenship as the Certified Federal Participant.⁵ No later than June 30, 2022, these answers regarding Anticipated Defendants will be published to the Defendants and become final. Subsequent to June 30, 2022, Certified Federal Participants will be estopped from seeking to alter the Anticipated Defendants and will be estopped from opposing the dismissal of a non-Anticipated Defendant from any proceeding in any tribunal. Notwithstanding anything in this Order to the

⁴ Brand Defendants refers to GSK, Pfizer, Boehringer Ingelheim, Sanofi, Patheon, and Chatterm.

⁵ Unless the Certified Federal Participant has a basis for federal jurisdiction other than diversity jurisdiction.

contrary, Certified Federal Participants who entered the Registry on or before February 28, 2022, will be estopped from amending an answer regarding an Anticipated Defendant, unless the Certified Federal Participant can provide: (1) a medical record, pharmacy record, loyalty record, or purchase receipt that supports the change(s), provided that the applicable record supporting such change(s) is ordered on or before May 15, 2022 but not received by June 24, 2022; (2) a record ordered by counsel prior to May 15, 2022 that the party to whom the request was submitted failed to produce to him or her despite reasonable follow up prior to June 24, 2022; (3) a record ordered prior to May 15, 2022 that, upon receipt and review, requires the Certified Federal Participant's counsel to order other records, so long as such additional records are ordered within forty-five (45) days of receipt of the prior record; or (4) any other reason that the Court deems fair and equitable. Additionally, notwithstanding anything in this Order to the contrary, a Certified Federal Participant who enters the Registry on or after March 1, 2022, may amend an answer regarding an Anticipated Defendant if the Certified Federal Participant can provide: (1) a medical record, pharmacy record, loyalty record, or purchase receipt that supports the change(s), provided that the applicable record supporting such change(s) is ordered on or before ninety (90) days after entering the Registry; (2) a record ordered on or before ninety (90) days after entering the Registry that, upon receipt and review, requires the Certified Federal Participant's counsel to order other records, so long as such additional records are ordered within forty-five (45) days of receipt of the prior record; or (3) any other reason that the Court deems fair and equitable.⁶

6. By participating in the certification process described in this Order, a Certified Federal Participant agrees that (i) he or she is estopped from filing a lawsuit concerning Zantac or any generic equivalent ranitidine product in a state court, unless any of the exceptions in

⁶ This Order shall not preclude the parties from reaching a contrary agreement concerning estoppel.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.